menu
    • menu
    [{"orgOrder":0,"company":"Purple Biotech","sponsor":"Menashe Bar-Eli","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"NT219","moa":"IRS1\/2","graph1":"Oncology","graph2":"Undisclosed","graph3":"Purple Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Purple Biotech \/ Menashe Bar-Eli","highestDevelopmentStatusID":"1","companyTruncated":"Purple Biotech \/ Menashe Bar-Eli"},{"orgOrder":0,"company":"Purple Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"CM-24","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Purple Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Purple Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Purple Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Purple Biotech","sponsor":"Immunorizon","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Large molecule","year":"2023","type":"Acquisition","leadProduct":"Tri-specific Antibody","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Purple Biotech","amount2":0.10000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Purple Biotech \/ Purple Biotech","highestDevelopmentStatusID":"4","companyTruncated":"Purple Biotech \/ Purple Biotech"}]

    Find Clinical Drug Pipeline Developments & Deals by Purple Biotech

    Menu

    Purple Biotech

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Purple Biotech

                            Israel arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Purple Biotech

                            Israel arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CM-24,Nivolumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Purple Biotech Announces First Patient Dosed in Open Label, Randomized Part of CM24 Phase 2 Clinical Trial

                            Details : CM24 is a first-in-class clinical stage mAb targeting CEACAM1, a novel immune checkpoint inhibitor with significant potential to treat multiple cancers.

                            Brand Name : CM-24

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            February 14, 2023

                            Lead Product(s) : CM-24,Nivolumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Purple Biotech

                            Israel arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Purple Biotech

                            Israel arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tri-specific Antibody

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Immunorizon

                            Deal Size : $101.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Purple Biotech Expands Pipeline of First-in-Class Therapeutics with Acquisition of Immunorizon and its Portfol...

                            Details : The acquisition will provide Purple Biotech with an expanded portfolio of investigational tri-specific antibody compounds that target multiple antigens and offer the potential to further expand to additional targets.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : $3.5 million

                            February 02, 2023

                            Lead Product(s) : Tri-specific Antibody

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Immunorizon

                            Deal Size : $101.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Purple Biotech

                            Israel arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Purple Biotech

                            Israel arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NT219,Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Menashe Bar-Eli

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Purple Biotech Expands Research Collaboration in Immuno-Oncology in Combination with NT219

                            Details : This collaboration will evaluate the potential efficacy of the combination of NT219, a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3, and immuno-oncology drugs, such as anti-CTLA4 or anti-PD1/PDL1 antibodies.

                            Brand Name : NT219

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 26, 2021

                            Lead Product(s) : NT219,Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Menashe Bar-Eli

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth